Slide 1: Stockholder Engagement
STOCKHOLDER ENGAGEMENT 1 Baxter International Inc. March 2025
Slide 2: Safe Harbor Statement
SA F E HA R BO R STAT EMENT 2Baxter International This presentation includes forward-looking statements concerning the company’s financial results (including the outlook for first-quarter and full-year 2025) and business development and regulatory activities. These forward-looking statements are bas
Slide 3: Executive Summary
3 Board of Directors and Management Updates > Following José Almeida’s departure, Brent Shafer appointed Chair and Interim CEO; Nancy Schlichting appointed Lead Independent Director; Heather Knight appointed COO and Interim Group President of Medical Products & Therapies > Continued focus on refresh
Slide 4: Recent Leadership Transition
R EC EN T L EA DER SHIP T R A NSIT IO N Board conducting a comprehensive and independent search process for a permanent CEO to succeed Mr. Almeida Baxter International 4 On February 3, 2025 Baxter announced key Board and management changes: > José Almeida ceased serving as Chair, President and Chief
Slide 5: New Baxter Profile
After completion of the recent Kidney Care sale, healthcare leader focused on providing an array of medical products and services across the care continuum FY 2024 Revenue by Segment Other Pharmaceuticals Medical Products & Therapies Healthcare Systems & Technologies $10.6B 23% 49% 28% <1% NEW BA XT
Slide 6: Strategic Actions Taken to Deliver Enhanced Shareholder Value
> On Jan. 31, 2025, Baxter completed the sale of its Kidney Care business, now known as Vantive, to Carlyle for ~$3.4 billion of net, after-tax proceeds > Completed the divestiture of the BioPharma Solutions (BPS) business at the end of Q3 2023. Utilizing ~$3.7 billion of net after-tax proceeds for
Slide 7: Highly Experienced and Qualified Board
Jeffrey (Jay) A. Craig Former Chair and CEO, Meritor Committee: AC* 7Baxter International 9 out of 10 Independent Directors ~4 Years of Average Tenure Board’s Independence and Refreshment AC = Audit Committee; CHC = Compensation and Human Capital Committee; NCGPP = Nominating, Corporate Governance a
Slide 8: Robust Engagement Year-Round
8Baxter International Robust Engagement Year-Round 2023 – Early 2024 Outreach Statistics1 Our Board, along with our Investor Relations team and other select members of the management team, is committed to engaging in constructive dialogue with stockholders on corporate governance, executive compensa
Slide 9: Executive Compensation Program
9Baxter International EXEC UT IVE C O MP ENSAT IO N P RO GR A M 2024 Executive Compensation Program Changes in Connection with Sale of Kidney Care Annual Incentive Plan The adjusted EPS and free cash flow performance curves were widened by 10% at threshold and 10% at maximum, requiring greater ach
Slide 10: Corporate Responsibility: Recognized for Making a Meaningful Difference
10Baxter International C O R P O R AT E R ESP O NSIB IL IT Y: R EC O GNIZ ED FO R MA K IN G A MEA NINGF UL D IF F ER ENC E Select Recognition Highlights For more information on Baxter’s efforts to benefit our communities, employees, and stakeholders, refer to our 2023 Corporate Responsibility Report